A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia (NAVIGATE-AD)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223321

Enrollment

Unknown

Registered

2016-09-20

Start date

2016-09-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Interventions

investigational material(s) Generic name etc : Experimental: Dose 1 LY3202626 INN of investigational material : Therapeutic category code : 119 Other agents affecting central nervous system Dosage an

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion Criteria: -Present with mild AD dementia based on the National Institute on Aging(NIA) and the Alzheimer's Association(AA) disease diagnostic criteria as determined by a qualified clinician approved by the Sponsor or designee. -Mini-Mental State Examination score of 20 to 26 inclusive at screening visit. -Has a florbetapir PET scan consistent with the presence of amyloid pathology at screening. Exclusion Criteria: -Significant neurological disease affecting the central nervous system (CNS), other than AD, that may affect cognition or ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinson's disease, multiple concussions, or epilepsy or recurrent seizures (except febrile childhood seizures). -Ocular pathology that significantly limits ability to reliably evaluate vision or the retina. -Use of strong inducers of cytochrome P450 3A (CYP3A) within 30 days before baseline. -Sensitivity to florbetapir or 18F-AV-1451. -Contraindication to MRI or PET or poor venous access for blood draws.

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026